iShares Biotechnology ETF
670 hedge funds and large institutions have $5.57B invested in iShares Biotechnology ETF in 2019 Q1 according to their latest regulatory filings, with 98 funds opening new positions, 192 increasing their positions, 234 reducing their positions, and 67 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
670
Holders Change
+21
Holders Change %
+3.24%
% of All Funds
14.52%
Holding in Top 10
15
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-16.67%
% of All Funds
0.33%
New
98
Increased
192
Reduced
234
Closed
67
Calls
$392M
Puts
$579M
Net Calls
-$186M
Net Calls Change
+$103M
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$190M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$152M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$95.6M |
| 4 |
Citigroup
New York
|
+$82.7M |
| 5 |
DFO
Duquesne Family Office
New York
|
+$49.3M |
Top Sellers
| 1 |
JPMorgan Chase & Co
New York
|
-$68.6M |
| 2 |
Millennium Management
New York
|
-$52.7M |
| 3 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$47.3M |
| 4 |
State of Tennessee, Department of Treasury
Nashville,
Tennessee
|
-$40.7M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$33.7M |
